Alnylam Pharmaceuticals, Inc.
POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF

Last updated:

Abstract:

The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting the ALAS1 gene, and methods of using such agents to alter (e.g., inhibit) expression of ALAS1 and to treat ALAS1 associated diseases, e.g., porphyria.

Status:
Application
Type:

Utility

Filling date:

23 Feb 2021

Issue date:

6 Jan 2022